- Home
- JWEL vs PSTV Comparison
JWEL vs PSTV Comparison
Compare JWEL & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JWEL
- PSTV
- Stock Information
- Founded
- JWEL 2012
- PSTV 1996
- Country
- JWEL China
- PSTV United States
- Employees
- JWEL N/A
- PSTV N/A
- Industry
- JWEL Other Consumer Services
- PSTV Medical/Dental Instruments
- Sector
- JWEL Consumer Discretionary
- PSTV Health Care
- Exchange
- JWEL Nasdaq
- PSTV Nasdaq
- Market Cap
- JWEL 6.0M
- PSTV 6.3M
- IPO Year
- JWEL 2021
- PSTV N/A
- Fundamental
- Price
- JWEL $2.91
- PSTV $1.30
- Analyst Decision
- JWEL
- PSTV Strong Buy
- Analyst Count
- JWEL 0
- PSTV 2
- Target Price
- JWEL N/A
- PSTV $13.50
- AVG Volume (30 Days)
- JWEL 17.0K
- PSTV 21.3K
- Earning Date
- JWEL 12-19-2024
- PSTV 03-04-2025
- Dividend Yield
- JWEL 7.34%
- PSTV N/A
- EPS Growth
- JWEL N/A
- PSTV N/A
- EPS
- JWEL N/A
- PSTV N/A
- Revenue
- JWEL $160,009,293.00
- PSTV $5,725,000.00
- Revenue This Year
- JWEL N/A
- PSTV $32.12
- Revenue Next Year
- JWEL N/A
- PSTV N/A
- P/E Ratio
- JWEL N/A
- PSTV N/A
- Revenue Growth
- JWEL N/A
- PSTV 52.63
- 52 Week Low
- JWEL $1.00
- PSTV $0.93
- 52 Week High
- JWEL $3.71
- PSTV $2.67
- Technical
- Relative Strength Index (RSI)
- JWEL 48.97
- PSTV 56.41
- Support Level
- JWEL $2.73
- PSTV $1.18
- Resistance Level
- JWEL $3.08
- PSTV $1.26
- Average True Range (ATR)
- JWEL 0.22
- PSTV 0.04
- MACD
- JWEL -0.03
- PSTV 0.01
- Stochastic Oscillator
- JWEL 41.38
- PSTV 90.00
About JWEL Jowell Global Ltd.
Jowell Global Ltd is a cosmetics, health and nutritional supplements, and household products e-commerce platform. It operates under Online Direct Sales, Authorized Retail Store Distribution, Third-party Merchants, and Live streaming marketing sales channels. The company's major merchandise categories are Cosmetic products, Health and nutritional supplements, and Household Products.
About PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).